Alnylam
Phone: +1 617 551 8200
Fax: +1 617 551 8101
| Type | Public |
|---|---|
| Traded as | Nasdaq: ALNY Russell 1000 Component |
| Industry | Pharmaceutical |
| Founded | 2002 |
| Headquarters | Cambridge, Massachusetts, US |
| Key people | Yvonne Greenstreet, (CEO) |
| Revenue |  US $219.75 million (2019) US $74.91 million (2018) |
| Number of employees | 1,323 (2019) |
| Website | alnylam.com |
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
For detailed contact information visit location pages below.
Alnylam's locations around the world
Clinical Trials sponsored by Alnylam
-
Alnylam PharmaceuticalsReclutamentoDown Syndrome-Associated Alzheimer's Disease (DS-AD)Stati Uniti, Spagna
-
Alnylam PharmaceuticalsReclutamentoAmiloidosi della tranhiretina con cardiomiopatiaStati Uniti, Belgio, Francia, Germania, Ungheria, Israele, Italia, Spagna, Svizzera, Regno Unito, Giappone, Taiwan, Slovacchia, Cina, Olanda, Hong Kong, Danimarca, Austria, Polonia, Turchia (Türkiye), Corea del Sud, Argentina, Australi... e altro ancora
-
Alnylam PharmaceuticalsReclutamentoCarcinoma epatocellulare avanzato | Carcinoma epatocellulare metastaticoStati Uniti, Italia, Corea del Sud
-
Alnylam PharmaceuticalsReclutamentoMalattia di HuntingtonGermania, Regno Unito, Canada
-
Alnylam PharmaceuticalsAttivo, non reclutanteAngiopatia amiloide cerebraleStati Uniti, Australia, Regno Unito, Svizzera, Olanda, Canada
-
Alnylam PharmaceuticalsCompletatoIpertensione da lieve a moderataGiappone
-
Alnylam PharmaceuticalsIscrizione su invitoAmiloidosi da transtiretina (ATTR) con cardiomiopatiaStati Uniti, Spagna, Regno Unito, Brasile, Portogallo, Argentina, Austria, Francia, Belgio, Italia, Danimarca, Svezia, Corea del Sud, Cechia, Olanda, Norvegia, Taiwan
-
Alnylam PharmaceuticalsCompletatoAmiloidosi mediata dalla transtiretinaRegno Unito
-
Alnylam PharmaceuticalsCompletatoAmiloidosi da transtiretina | Amiloidosi, ereditariaStati Uniti, Germania, Spagna, Regno Unito, Francia, Portogallo, Taiwan, Giappone, Bulgaria, Belgio, Grecia, Italia, Svezia, Corea del Sud, Argentina, Australia, Brasile, Canada, Cipro, Malaysia, Messico, Olanda
-
Alnylam PharmaceuticalsCompletatoIpertensioneStati Uniti, Canada, Regno Unito, Lettonia, Lituania, Polonia, Estonia, Germania